💊 Vepdegestrant (PROTAC-based Cancer Therapy)
Context: Vepdegestrant has emerged as one of the world's first successful PROTAC-based targeted protein degraders, offering a new treatment option for patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer by eliminating the cancer-driving estrogen receptor rather than merely blocking it.
📖 PRELIMS POINTER
🔹 What is Vepdegestrant?
- Vepdegestrant is a first-in-class, orally administered PROTAC (Proteolysis Targeting Chimera) medicine designed to selectively destroy disease-causing proteins.
- Unlike conventional drugs that inhibit protein activity, it harnesses the cell's natural protein recycling system to permanently eliminate the target protein.
- It is specifically developed for treating ESR1-mutated, Estrogen Receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer, particularly in patients whose cancers have become resistant to hormone therapy.
- Developed by: Arvinas Inc. and Pfizer.
🎯 Therapeutic Target
- Targets the Estrogen Receptor (ER), a major driver of hormone-sensitive breast cancers.
- Designed to overcome resistance caused by ESR1 gene mutations, which commonly develop after prolonged endocrine therapy.
- Applicable in advanced and metastatic breast cancers that no longer respond adequately to conventional hormone-blocking medicines.
⚙ How Does PROTAC Technology Work?
- Step 1: Dual Binding
- The PROTAC molecule simultaneously binds:
- The target protein (Estrogen Receptor)
- An E3 ubiquitin ligase enzyme
- The PROTAC molecule simultaneously binds:
- Step 2: Formation of Ternary Complex
- Brings both proteins into close proximity, initiating targeted protein degradation.
- Step 3: Ubiquitination
- The E3 ligase attaches multiple ubiquitin molecules to the estrogen receptor, marking it for destruction.
- Step 4: Proteasomal Degradation
- The tagged protein is destroyed by the cell's proteasome into harmless amino acids.
- Step 5: Catalytic Recycling
- The PROTAC molecule remains intact and can repeatedly degrade multiple target proteins.
⭐ Key Features
- Targeted Protein Degradation
- Eliminates the estrogen receptor instead of merely suppressing its activity.
- Catalytic Mechanism
- One molecule can degrade multiple protein molecules, improving therapeutic efficiency.
- Oral Administration
- Available as a once-daily oral tablet, improving patient convenience compared to injectable therapies.
- Overcomes Drug Resistance
- Effective against cancers that have developed resistance due to ESR1 mutations.
- Clinical Evidence
- Phase III clinical trial demonstrated improved progression-free survival compared with fulvestrant in eligible patients.
- Safety Profile
- Common adverse effects include fatigue, nausea, muscle pain, and mild transient liver enzyme abnormalities.
🌍 Significance
- Represents a major breakthrough in precision oncology.
- Validates PROTAC technology as a new class of therapeutics capable of targeting previously "undruggable" proteins.
- Provides an effective treatment option for patients with hormone-resistant metastatic breast cancer.
- May pave the way for similar therapies against cancers, neurological disorders, and other protein-driven diseases.
UPSC Takeaway:
Vepdegestrant is a next-generation PROTAC-based targeted protein degrader that treats ESR1-mutated ER-positive, HER2-negative advanced breast cancer by destroying the estrogen receptor rather than simply inhibiting it. It marks a significant advancement in precision medicine and demonstrates the growing potential of targeted protein degradation as a transformative approach in cancer therapy.
Vepdegestrant is a next-generation PROTAC-based targeted protein degrader that treats ESR1-mutated ER-positive, HER2-negative advanced breast cancer by destroying the estrogen receptor rather than simply inhibiting it. It marks a significant advancement in precision medicine and demonstrates the growing potential of targeted protein degradation as a transformative approach in cancer therapy.